Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56 results about "Orphan receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In biochemistry, an orphan receptor is a protein that has a similar structure to other identified receptors but whose endogenous ligand has not yet been identified. If a ligand for an orphan receptor is later discovered, the receptor is referred to as an "adopted orphan". Conversely, the term orphan ligand refers to a biological ligand whose cognate receptor has not yet been identified.
Modulators of retinoid-related orphan receptor gamma
InactiveUS8389739B1Increase the number ofImproving immunogenicityBiocideSteroidsRetinoid-Related Orphan Receptor-GammaRetinoid-Related Orphan Receptor
Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor γ (RORγ) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and / or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of RORγ results in stimulation of TH-17 cell function and / or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
Owner:ORPHAGEN PHARMA INC
Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells
InactiveUS20070196335A1Limiting uncontrolled T cell activationImproving DC-based therapyBiocideGenetic material ingredientsDendritic cellApoptosis
Mitogen induced nuclear orphan receptor (MINOR) is described as inducing apoptosis in dendritic cells (DCs). Downregulation of its expression results in a downregulation of apoptosis. A novel approach of inhibiting DC apoptosis is described employing small interfering RNA (siRNA) that targets MINOR. Improved DC-based vaccines exhibiting longer lifespan of DCs, increased potency of DCs, and enhanced immunogenicity are described.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Substituted phenol and application thereof as receptor TR3 excitant
Disclosed are substituted benzene and the application thereof to be used as agonist for receptor TR3, relating to substituted benzene. The invention provides a substituted phenol derivative compound and the application thereof to be used as agonist for orphan receptor TR3, in particular to the application in preparing the medicine for curing hypoglycemia and diseases related to abnormal apoptosis of cells, such as cancer. The substituted benzene and the substituted phenol derivative compound are respectively denoted by structural formula I and structural formula II; wherein R1 is nitrophthalimides or other alcoxyl-acyl or alcoxyl-acyl-alkyl, R2 is n-octanoyl, or other alkyl-acyl, or alkyl-acyl-alkyl, or alkyl, and R3, R4, R5 and R6 are H, OH, NH2 or halogen atoms.
Owner:XIAMEN UNIV
Methods and compositions for identifying receptor effectors
InactiveUS7319009B2Quick filterRapid and reliable and effective assaySugar derivativesMicroorganismsAgonistCellular receptor
The present invention makes available rapid, effective assays for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assays enable rapid screening of large numbers of polypeptides in a library to identify those polypeptides which induce or antagonize receptor bioactivity. The subject assays are particularly amenable for identifying agonists and antagonists for orphan receptors. In particular the present invention makes available novel ligand agonists of human formyl peptide receptor like-1 (FPRL-1) receptors. These novel ligand agonists are used in the assays of the invention to identify modulators of FPRL-1 receptor.
Owner:CADUS TECH
Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
The present invention relates to novel retinoid-related orphan receptor gamma (ROR gamma) modulators and their use in the treatment of diseases mediated by ROR gamma.
Owner:GLAXO GRP LTD
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
InactiveCN106132422AAntibacterial agentsBacterial antigen ingredientsAdoptive cellular therapyDendritic cell
The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR gamma) and provides adoptive cellular therapies using an agonist of ROR gamma, populations of lymphocyte cells that have been exposed to an agonist of ROR gamma, populations of dendritic cells that have been exposed to an agonist of ROR gamma, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and / or dendritic cells in a patient by administering an agonist of ROR gamma to a patient.
Owner:LICELLA PTY LTD
Anti-ror1 antibodies
ActiveUS20180142016A1Easy to understandEffectively prevent Wnt5a from bindingDipeptide ingredientsAntibody mimetics/scaffoldsNucleotideCancer therapy
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
Owner:EUREKA THERAPEUTICS INC
Method of determining ligand
InactiveUS20050118639A1Efficiently determinedBiological material analysisReceptors for hormonesReceptorFluorescent protein
The present invention aims at providing a method of determining a ligand to an orphan receptor. Specifically, the present invention provides a method of determining a ligand to a receptor protein, to which no ligand has been determined, which comprises using a fusion protein of the receptor protein and a fluorescent protein.
Owner:TAKEDA PHARMA CO LTD
Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
ActiveUS20150299121A1Nervous disorderOrganic chemistryImmunologic disordersRetinoid-Related Orphan Receptor
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
Owner:GLAXO GROUP LTD
Compound used as RORgamma conditioning agent
The present invention relates to a compound which can be used as a retinoid-related orphan receptor γ (RORγ) modifier, a pharmaceutical composition of said compound, the use of said compound in the manufacture of pharmaceuticals, and a method for using said compound for treatment and / or prophylaxis of a RORγ-mediated disease in a mammal (especially a human). The compound has the structural formula I.
Owner:BEIJING HANMI PHARMA CO LTD
Novel compounds
ActiveUS20170197978A1Organic active ingredientsNervous disorderRetinoid-Related Orphan Receptor-GammaDisease
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Anti-ROR2 Antibodies
ActiveUS20180127503A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntiendomysial antibodiesTyrosine
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1
Polypeptides derived from retinoic acid-related orphan receptor(ror) and their applications
The invention relates to polypeptides derived from the retinoic acid-related orphan receptor (ROR) in mammals, characterized in that they are delimited in their N-terminal extremity by an amino-acid located between positions 1 to 209, and in their C-terminal extremity by an amino-acid located between positions 450 to 452 of the rat RORbeta, alpha, or gamma, or by an amino-acid located at corresponding positions in nuclear receptor ROR of other subtypes than alpha, beta and gamma, and / or of the other mammals. The invention also relates to the use of these polypeptides, or of the molecular complexes or the crystals containing them, for carrying out:-a process for the screening of a ROR-LBD ligand which is an agonist, or an antagonist of said receptor,-or a process for the analysis of the tridimensional structure of the complexes formed with said polypeptides, molecular complexes or crystals and a particular compound.
Owner:CENT NAT DE LA RECHERCHE SCI
Novel compounds
ActiveUS20170101399A1Organic active ingredientsNervous disorderRetinoid-Related Orphan Receptor-GammaDisease
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Compounds and methods
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
Owner:TEMPERO PHARMA
Ror1 car t-cells
PendingCN110997709APolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorTyrosine
There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor (ROR1), and its use. Also described is a T cell comprising the CAR and its use in the treatment of cancer.
Owner:UCL BUSINESS PLC
Retinoic acid receptor-related orphan receptor modulators and uses thereof
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Owner:INNOV17
Err inverse agonists
PendingUS20200247792A1Group 3/13 element organic compoundsPharmaceutical active ingredientsEstrogen receptorPharmaceutical formulation
In one aspect, the present disclosure describes new estrogen receptor-related orphan receptor (EER) inverse agonist compounds. Also described are pharmaceutical formulations, methods of synthesis and uses thereof.
Owner:SAINT LOUIS UNIVERSITY
Methods of Identifying Antibodies to Ligands of Orphan Receptors
Described is a method of identifying antibodies against hitherto unknown ligands of orphan receptors or other orphan ligands, i.e., receptors or other ligands where the counter-ligand has not yet been identified. The availability of antibodies binding to the unknown ligand significantly facilitates their isolation and characterization, and the identified antibodies can themselves be useful for treating patients with cancer or autoimmune diseases, or other disorders. An exemplary embodiment provides for a method designated Identification of Therapeutic Antibodies by Competitive Screening (ITACS). Described are also fusion proteins comprising a soluble portion of an orphan receptor, such as NKp30, and the Fc portion of an antibody. The fusion proteins typically comprise a Flexible Transmembrane Linker (FTL), i.e., a linker comprising a portion of a transmembrane domain of the orphan receptor.
Owner:NOVO NORDISK AS
Schistosoma japonicum recombinant antigen, and preparation method and application thereof
The invention discloses a Schistosoma japonicum recombinant antigen. The recombinant antigen is prepared through expressing a recombinant vector containing first extramembrane fragment gene at the N-end of a Schistosoma japonicum trispanning orphan receptor. The invention also discloses a preparation method of the Schistosoma japonicum recombinant antigen, and an application of the Schistosoma japonicum recombinant antigen in preparation of schistosomiasis prevention or treatment vaccines or drugs. The Schistosoma japonicum recombinant antigen in mouse immunization experiments can induce generation of anti-recombinant antigen specific IgG, IgG1 and IgG2a antibodies and allows the antibodies to reach a high level, and the Schistosoma japonicum recombinant antigen in animal protection experiments induces the worm reduction rate of 32.4% and the ovum reduction rate of 41.41%, so the recombinant antigen is suitable for being used as an anti-schistosomiasis candidate vaccine, and has very good application prospect.
Owner:SHANGHAI VETERINARY RES INST CHINESE ACAD OF AGRI SCI
Modulators of retinoid-related orphan receptor gamma
InactiveUS20130150333A1Increase the number ofImproving immunogenicityBiocidePeptide/protein ingredientsRetinoid-Related Orphan ReceptorRetinoid-Related Orphan Receptor-Gamma
Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor γ (RORγ) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and / or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of RORγ results in stimulation of TH-17 cell function and / or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
Owner:ORPHAGEN PHARMA INC
Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof
Provided herein are compounds of the formulas (I) and (II):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Owner:INNOV17
Detection method for insertion/deletion polymorphism of sheep RORA (retinoid acid receptor related orphan receptor A) gene, primer pair and application
ActiveCN111088369AAccurate detectionLow costMicrobiological testing/measurementDNA/RNA fragmentationElectrophoresesIndel polymorphism
The invention relates to a detection method for insertion / deletion polymorphism of a sheep RORA (retinoid acid receptor related orphan receptor A) gene. The detection method comprises the following steps: by taking genome DNA (deoxyribonucleic acid) of sheep to be detected as a template, and a primer pair as amplification primers, performing PCR (polymerase chain reaction) amplification on a fragment with insertion / deletion polymorphic sites in a sheep RORA gene intron region, performing electrophoresis on an amplification product, and identifying genotypes of the insertion / deletion polymorphic sites according to electrophoresis results, wherein the insertion / deletion polymorphic sites are selected from 23-bp insertion / deletion polymorphic sites of NC_040258.1:S.10400_10423 sites of the sheep RORA gene. By adopting the method, the genotypes of the insertion / deletion polymorphic sites can be simply, rapidly and precisely detected with low cost.
Owner:天津奥群牧业有限公司
Anti-ROR1 antibodies
ActiveUS11155615B2Simple structureEffectively prevent Wnt5a from bindingDipeptide ingredientsAntibody mimetics/scaffoldsAntiendomysial antibodiesTyrosine
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
Owner:EUREKA THERAPEUTICS INC
Anticancer application of sesquiterpene
InactiveCN102114007AInduce apoptosisHydroxy compound active ingredientsDigestive systemCancer cellApoptosis
The invention relates to an anticancer application of sesquiterpene, particularly provides application of sesquiterpene ths-cy-7 in preparing anticancer drugs and application of orphan receptor Nur77 as a target in screening marine living resources. The sesquiterpene ths-cy-7 can induce apoptosis of cancer cells and expression of orphan receptor Nur77, and the apoptotic effect on cancer cells is dependent on the extranuclear expression of Nur77. The sesquiterpene ths-cy-7, as a regulatory factor targeting Nur77 apoptotic pathway, becomes a very effective therapeutic drug on cancer. The anticancer drugs use the orphan receptor Nur77 as an action target.
Owner:XIAMEN UNIV
Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof
InactiveUS20160024052A1Useful in treatmentBiocideOrganic chemistryRetinoic acid receptorReceptor for activated C kinase 1
Provided herein are compounds of the formulas (I) and (II):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Owner:INNOV17
Application of alkannin derivant
The invention provides an application of alkannin derivant for preparing drug treating cancers, and the drug takes orphan receptor Nur77 as an effect target. The invention also provides the application of the orphan receptor Nur77 which serves as an effect target to screen alkannin derivant. The alkannin derivant of the invention clarifies the mechanism of the anti-tumour effect of alkannin derivant via a great discovery that tumour cells are induced to apoptosis by acting on the orphan receptor Nur77, and provides effective target spots for decorating and optimizing the structure.
Owner:XIAMEN UNIV
Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereof
Provided herein are compounds of the formulas (I) and (II):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Owner:INNOV17
Retinoic acid receptor-related orphan receptor modulators and uses thereof
InactiveUS20150252051A1BiocideOrganic chemistryReceptor for activated C kinase 1Retinoic acid receptor alpha
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Owner:INNOV17
Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Owner:INNOV17
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com